

1 Electronic Supplementary information (ESI)

2 **High-Performance Cation Electrokinetic Concentrator**  
3 **Based on  $\gamma$ -CD/QCS/PVA Composite and Microchip for**  
4 **Evaluating the Activity of P-glycoprotein with**  
5 **Interference-Free from Serum Albumin**

6 Runhui Zhang<sup>1#</sup>, Jun Xu<sup>1#</sup>, Jieqi Deng<sup>1</sup>, Wei Ouyang<sup>2</sup>, Hanren Chen<sup>1</sup>, Qing Tang<sup>1</sup>,

7 Shiquan Zheng<sup>1</sup>, Lihong Liu<sup>1\*</sup>

8 <sup>1</sup>NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong  
9 Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences,  
10 Southern Medical University, Guangzhou, 510515, China

11 <sup>2</sup>Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, IL  
12 60208, United States

13 # These authors contributed equally to this work.

14 \*Corresponding Author

15 NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial  
16 Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical  
17 University, Guangzhou, 510515, China; orcid.org/0000-0003-3631-2148;  
18 Email: lhliu@smu.edu.cn (L. Liu)

19

20 **Contents**

|    |  |    |
|----|--|----|
| 21 | Materials and reagents .....   | 2  |
| 22 | Experimental Section .....   | 3  |
| 23 | Scheme S1. Schematic diagram of quaternized chitosan synthesis .....                             | 5  |
| 24 | Fig. S1 AEM line on the glass substrate after the PDMS mold was removed.....                     | 6  |
| 25 | Fig. S2 FTIR spectra of CS, QCS, and $\gamma$ -CD/QCS/PVA AEM.....                               | 7  |
| 26 | Fig. S3 SEM of the AEM composite in hydrated state. A: SEM of surface; B: SEM of section. ....   | 8  |
| 27 | Fig. S4 Images of the channel before (A) and after (B) AEM; Images of both sides of the channel  |    |
| 28 | with AEM, (C) left sides, (D) right sides.....   | 9  |
| 29 | Fig. S5 Stacking band of different cationic analyte.....   | 10 |
| 30 | Fig. S6 Effect of the content of PVA on electrokinetic concentration performance of the system.  | 11 |
| 31 | Fig. S7 Effect of the contents of QCS on electrokinetic concentration performance of the system. |    |
| 32 | .....  | 12 |

|    |  |    |
|----|--|----|
| 33 | Fig. S8 Effects of different contents of $\gamma$ -CD on electrokinetic concentration of CEC.....      | 13 |
| 34 | Fig. S9 Effects of different types of CD on electrokinetic concentration of CEC.....                   | 14 |
| 35 | Fig. S10 Effect of the different concentration of the $\gamma$ -CD/QCS/PVA composite on CEC enrichment |    |
| 36 | performance. ....  | 15 |
| 37 | Fig. S11 Effects of PBS concentrations on fluorescent bands of 1 nM Rho 123. ....                      | 16 |
| 38 | Fig. S12 Effects of serum concentrations on fluorescent bands.of 1 nM Rho 123.....                     | 17 |
| 39 | Fig. S13 Effects of different storing time of $\gamma$ -CD/QCS/PVA composite on fluorescent bands of 1 |    |
| 40 | nM Rho 123. ....   | 18 |
| 41 | Fig. S14 Reusability of one CEC-Y. The buffer was 0.5 $\times$ PBS, the sample was 1 nM Rho 123. ..    | 19 |
| 42 | Fig. S15 Reusability of one CEC-Y on Rho 123 (1 nM) in 1% serum sample. ....                           | 20 |
| 43 | Fig. S16 The cytotoxicity of VER and 18 $\alpha$ -GA on Caco-2. ....                                   | 21 |
| 44 | Table S1 Comparison of previously reported electrokinetic concentrators with our work .....            | 22 |
| 45 | Table S2. Ranges for the examined parameters and the selected optimal mass proportion of each          |    |
| 46 | component of AEM based fluorescence intensity.....   | 23 |
| 47 | Table S3. Comparison of the methods on the analysis of Rho 123 .....                                   | 24 |
| 48 | Table S4. Spiked results of Rho123 in 1% serum and 0.3% Cell culture medium sample .....               | 25 |
| 49 | Table S5. The approximate material cost of the CEC.....  | 26 |
| 50 | Table S6. Pharmacokinetic parameters of Rho123 in rats after intragastrical administration of          |    |
| 51 | Rho123 with or without treatment of VER.....   | 27 |
| 52 | Table S7 List of Abbreviations .....   | 28 |

53

#### 54 **Materials and reagents**

55 Chitosan (CS) and polyvinyl alcohol (PVA) were purchased from China National Pharmaceutical Group  
56 Corporation (Beijing, China) and Sangon Biotech Co., Ltd. (Shanghai, China), respectively.  $\gamma$ -  
57 cyclodextrin ( $\gamma$ -CD), glutaraldehyde (GA), melamine (MA), 2,3-epoxy propyl trimethyl ammonium  
58 chloride (GTAC), verapamil (VER) and 18  $\alpha$  - glycyrrhetic acid (18  $\alpha$  - GA) were provided by Shanghai  
59 Macklin Biochemical Co., Ltd. (Shanghai, China). Phosphate buffered saline (PBS, pH=7.4) was  
60 supplied by Guangzhou Alexan Biotech company (Guangzhou, China). Platinum wire electrode was  
61 purchased from Xiya Reagents (Shandong, China). Poly dimethyl diallyl ammonium chloride  
62 (PDADMAC) was supplied by Sigma-Aldrich (Shanghai, China). Sylgrd 184 silicone elastomer  
63 polydimethylsiloxane (PDMS) was provided by Dow Corning (Midland, MI, USA). Rhodamine 123  
64 (Rho123) was purchased from Yuanye Biotechnology Co., Ltd. (Shanghai, China). Fluorescence was  
65 recorded using an inverted fluorescence microscope (Leica DMIL LED, Ernst & Company, Vetzlar,  
66 Germany) equipped with a CCD camera (Leica DFC 360 FX) and quantified by the free software ImageJ.  
67 A DC power supply (MP3001D, Maisheng, Dongguan, China) was used to supply DC voltages for on-  
68 line electrokinetic concentration. The physical structure of AEMs were characterized using TEM (Hitach.  
69 H, Tokyo, Japan). The chemical structures of CS, QCS and AEMs were confirmed by FTIR (Jasco Inc.,  
70 Easton, MD, USA).

71 The Caco-2 cells were supplied by the Chinese Academy of Sciences and cultured in Minimum  
72 Essential Medium (MEM) (Procell Life Science & Technology Co. Ltd., Wuhan, China) containing 10%  
73 fetal bovine serum (FBS) (Excellbio Biological Products Co. Ltd., Shanghai, China) and 1% penicillin  
74 and streptomycin (P/S) (Gibco, Thermo Fisher Scientific, Shanghai, China) at 37  $^{\circ}$ C under a humidified  
75 5% CO<sub>2</sub> conventional conditions in a cell incubator (Yiheng Scientific Instrument Co. Ltd., Shanghai,  
76 China). A 24-well Transwell chamber (Corning, USA) was used to seed Caco-2 cells. The cell viability

77 of Caco-2 cells was detected by CCK-8 kit (Sigma, USA) and using a SpectraMax i3x Multi-Mode  
78 microplate reader (Molecular Devices, USA) to detect the optical density.

## 79 **Experimental Section**

### 80 *1. Modification of the channel walls with PDDAC*

81 The microfluidic chip was loaded with 0.1% PDDAC solution and equilibrated at room temperature for  
82 5 min, then the channels were thoroughly rinsed with water and used immediately without further  
83 treatment. PDDAC forms an electrostatic adsorption monolayer on the microchannel walls, resulting in  
84 a positive net charge on the microchannel walls and a reverse EOF in the microchannel under electric  
85 field.

### 86 *2. Establishment of Caco-2 Cell Model*

87 A 24-well Transwell chamber was used to seed  $2 \times 10^5$  Caco-2 cells and supplied with MEM (containing  
88 12% FBS and 1% P/S) for Transwell cell culture, which added 600  $\mu$ l medium in basolateral (BL) side  
89 and 300  $\mu$ l medium in apical (AP) side. The medium was changed every 2 days in the first week, and  
90 changed once daily in the rest experimental days. When the cells were cultured in the Transwell chamber  
91 to the tenth day, the trans-epithelial electrical resistance (TEER) was measured every 3 days to determine  
92 the growth of Caco-2 cells. Figure S9b shows that after 21 days of growing on Transwell inserts, the  
93 Caco-2 cells had formed an intact and confluent epithelial cell layer that can be used for further studies

### 94 *3. Determination of Cell viability*

95 VER was selected as a P-gp expression inhibitor in Caco-2 cell model, and 18 $\alpha$ -GA was used as a P-gp  
96 expression agonist in Caco-2 cell model. Next, we investigated the cytotoxicity of the two drugs as  
97 follows.

98 Caco-2 cells were seeded in a 96-well plate at a density of 5,000 cells per well and incubated for 24 h,  
99 then the cells were incubated with different concentrations of 18 $\alpha$ -GA (10  $\mu$ M, 50  $\mu$ M, 100  $\mu$ M) and  
100 VER (10  $\mu$ M, 50  $\mu$ M, 100  $\mu$ M) in combination with Rho 123 (10  $\mu$ M) for 12 h, respectively. The viability  
101 of Caco-2 cells was determined by the Cell Counting Kit-8 (CCK-8) assay according to the  
102 manufacturer's instruction. Briefly, the cultured cells were rinsed with 200  $\mu$ l PBS/well three times, and  
103 added 10  $\mu$ l CCK-8 solution to each well, then optical density was detected at 450 nm using a SpectraMax  
104 i3x Multi-Mode microplate reader after another 2 h incubation.

### 105 *4. Establishment of standard curves for Rho123*

106 The fluorescence intensity of a series of Rho123 gradient concentration of standard solution (10-3000  
107 pM) was measured using CEC, Image J was used to process the fluorescence intensity (y) of all the Image  
108 fluorescence bands, and the standard curve of fluorescence intensity (y) versus concentration (x) was  
109 described.

### 110 *5. Statistical analysis*

111 The fluorescence intensity of the samples obtained from our enrichment platform at a certain  
112 concentration dilution in bidirectional transport experiment was taken into the standard curve, and the  
113 concentration at each time point was calculated. The apparent permeability coefficients (Papp) were  
114 calculated in bidirectional transport experiments according to the following equation (2):

115  $P_{app} = (dQ/dt)/(1/(A \times C_0))$  (1)

116 Where  $dQ/dt$  ( $\mu\text{mol/s}$ ) is the slope of the cumulative amount transported in the receiving chamber,  $C_0$   
117 ( $\mu\text{mol/L}$ ) is the initial concentration of Rho123, and  $A$  ( $0.33\text{cm}^2$ ) is the surface area of the cell  
118 monolayer.

119 Efflux ratios (ER) were calculated according to the following equation (3):


120  $ER = P_{app_{BL-AP}}/P_{app_{AP-BL}}$  (2)

121 Pharmacokinetic parameters, including the area under the plasma concentration-time curve (AUC),  
122 maximal plasma concentration ( $C_{\text{max}}$ ) etc. Pharmacokinetic parameters were calculated using the DAS  
123 3.0 pharmacokinetic software (Chinese Pharmacological Association, Anhui, China).

124 Data were presented as mean and standard deviation, and the data analysis was performed using  
125 SPSS19.0 package (IBM SPSS Inc, Chicago, IL). The differences between the mean values were  
126 analyzed for significance using a one-way analysis of variance (ANOVA). In all statistical analyses,  
127 values of  $P < 0.05$  were considered to indicate statistically significant.

128

129




130

131 **Scheme S1.** Schematic diagram of quaternized chitosan synthesis

132

133




134

135

**Fig. S1** AEM line on the glass substrate after the PDMS mold was removed.

136

137




139

140 **Fig. S2** FTIR spectra of CS, QCS, and  $\gamma$ -CD/QCS/PVA AEM. In FTIR, the absorption peak at 1480  
 141  $\text{cm}^{-1}$  was attributed to the bending vibration of C-H in the quaternary amine group. A characteristic peak  
 142 appeared at 1644  $\text{cm}^{-1}$ , which successfully proved that the primary amine of chitosan backbone had been  
 143 changed into a secondary amine structure. The appearance of the characteristic C-O-C peak at 1025  $\text{cm}^{-1}$   
 144  $^{-1}$  can be seen after the addition of  $\gamma$ -CD. In addition, in FTIR of  $\gamma$ -CD/QCS/PVA AEM, the C-O stretching  
 145 vibration peak at 1415  $\text{cm}^{-1}$  was formed by the acetal reaction between -OH and -CHO, and the -CH  
 146 stretching vibration peak of the aldehyde group appeared at 2910  $\text{cm}^{-1}$ , which indicated that the cross-  
 147 linking reaction occurred in the AEM interior.

148

149




150

151 **Fig. S3** SEM of the AEM composite in hydrated state. A: SEM of surface; B: SEM of section.

152




153



154

155 **Fig. S4** Images around the AFM membrane in the channel. (A) Front. (B) Back. (C) Left. (D) Right.

156




157

158 **Fig. S5** Stacking band of different cationic analyte, including Cationic Brilliant Red (CBR),  
 159 Berberine (BER) and Rho 123. Conditions: 0.1% PDDAC on the inner surface of the microchannel,  
 160  $\gamma$ -CD/PVA/QCS AEM (3% PVA, 1%QCS, 2% GA, 2% MA and 1.5%  $\gamma$ -CD); 1 nM Rho 123; buffer  
 161  $0.5 \times$  PBS (pH 3.5); AEM microchannel dimension: 200  $\mu$ m width and 45  $\mu$ m depth; 150 V voltage.

162

163




164

165 **Fig. S6** Effect of the content of PVA on electrokinetic concentration performance of the system.

166 Conditions: AEM (1%QCS, 3% PVA, 2% GA, 2% MA), other conditions as in **Fig. S5**.


167




168

169 **Fig. S7** Effect of the contents of QCS on electrokinetic concentration performance of the system.

170 Conditions: AEM (3% PVA, 2% GA, 2% MA), other conditions as in **Fig. S5**.




171  
172 **Fig. S8** Effects of different contents of  $\gamma$ -CD on electrokinetic concentration of CEC. Conditions:  
173 AEM (3% PVA, 1% QCS, 2% GA and 2% MA), other conditions as in **Fig. S5**.  
174



175


176 **Fig. S9** Effects of different types of CD on electrokinetic concentration of CEC. (a: QCS/PVA  
177 AEM, b:  $\alpha$ -CD/QCS-PVA AEM, c:  $\beta$ -CD/QCS-PVA AEM, d:  $\gamma$ -CD/QCS-PVA AEM). Other  
178 conditions as in **Fig. S5**.



180

181 **Fig. S10** Effect of the different concentration of the  $\gamma$ -CD/QCS/PVA composite on CEC enrichment  
 182 performance. Conditions: 0.1% PDDAC on the inner surface of the microchannel,  $\gamma$ -CD/PVA/QCS  
 183 AEM (PVA : QCS : GA : MA :  $\gamma$ -CD = 3:1:2:2:1.5); 1 nM Rho 123; buffer  $0.5 \times$  PBS (pH 3.5);  
 184 AEM microchannel dimension: 200  $\mu$ m width and 45  $\mu$ m depth; 150 V voltage.  
 185

186




187

188 **Fig. S11** Effects of PBS concentrations on fluorescent bands of 1 nM Rho 123.

189






190

191 **Fig. S12** Effects of serum concentrations on fluorescent bands of 1 nM Rho 123.


192



193

194 **Fig. S13** Effects of different storing time of  $\gamma$ -CD/QCS/PVA composite on fluorescent bands of 1  
195 nM Rho 123.

196




197

198

**Fig. S14** Reusability of one CEC-Y. The buffer was 0.5  $\times$  PBS, the sample was 1 nM Rho 123.

199



200


201

**Fig. S15** Reusability of one CEC-Y on Rho 123 (1 nM) in 1% serum sample.

202

203

204



205

206 **Fig. S16** The cytotoxicity of VER and 18α-GA on Caco-2 was investigated by CCK-8 (a). The

207 relationship between the transmembrane resistance of Caco -2 monolayer cells and the growth time

208 (b)

209

210

211

212

**Table S1.** Comparison of previously reported electrokinetic concentrators with our work

| Nanochannel permselectivity | Nanochannel fabrication method           | Permselective material      | Enrichment factor | Ref.      |
|-----------------------------|--|-----------------------------|-------------------|-----------|
| Anion permselective         | AEM solution patterning                  | $\gamma$ -CD/PVA/QCS AEM    | 120000            | This work |
|                             | Salt leaching technique                  | PPO <sup>a)</sup> AEM       | 500               | [1]       |
|                             | Cationic gel photopolymerization         | Cationic polyacrylamide gel | 6400              | [2]       |
|                             | Lithography and cationic polymer coating | TMSVE <sup>d)</sup>         | 500               | [3]       |

213 a) Poly (2,6-dimethyl 1,4-phenylene) oxide; b) Fluorescein isothiocyanate; c) Tris(bipyridine) ruthenium (II) chloride; d) N-[3- (trimethoxysilyl)propyl]-N'-(4-  
 214 vinylbenzyl) ethylenediamine hydrochloride; e) C-reactive protein; f) Bovine serum albumin

215

216 **Table S2.** Ranges for the examined parameters and the selected optimal mass proportion of each  
217 component of AEM based fluorescence intensity.

| <b>Parameters</b> | <b>Ranges (%)</b> | <b>Selected values (%)</b> |
|-------------------|-------------------|----------------------------|
| PVA               | 0.5 – 4           | 3                          |
| QCS               | 0.25 – 2          | 1                          |
| $\gamma$ -CD      | 0 – 2.5           | 1.5                        |

218

219

**Table S3.** Comparison of the methods on the analysis of Rho 123

| Methods   | LOD                | Ref       |
|-----------|--------------------|-----------|
| HPLC      | 105 pM (40 pg/mL)  | [4]       |
| CE-LIF    | 50 pM              | [5]       |
| MEKC-LIF  | 263 pM (100 pg/mL) | [6]       |
| LC-ESI-MS | 2.6 nM (1 ng/mL)   | [7]       |
| CEC       | 2.6 pM             | This work |

220 HPLC: high performance liquid chromatography; CE-LIF: capillary electrophoresis-laser-induced  
 221 fluorescence; MEKC-LIF: micellar electrokinetic chromatograph-laser-induced fluorescence; LC-  
 222 ESI-MS: Liquid chromatography - electrospray ionization mass spectrometry.  
 223



224 **Table S4.** Spiked results of Rho123 in 1% serum and 0.3% Cell culture medium sample

| Sample              | Spiked (pM) | Found (pM) | Recovery (%) | Average (%) | RSD (%) |
|---------------------|-------------|------------|--------------|-------------|---------|
| Serum               | 50          | 56         | 112.0        | 104.7       | 3.7     |
|                     | 500         | 481        | 96.2         |             | 2.9     |
|                     | 2000        | 2174       | 108.7        |             | 2.7     |
| Cell culture medium | 50          | 55         | 110.7        | 103.5       | 5.80    |
|                     | 500         | 512        | 102.4        |             | 5.60    |
|                     | 2000        | 1946       | 97.3         |             | 4.10    |

225

226

227

**Table S5.** The approximate material cost of the CEC

|                                | Description  | Supplier   | Order unit |        | CEC          |               |
|--------------------------------|--------------|--|------------|--------|--------------|---------------|
|                                |              |  | Quantity   | Price  | Quantity     | Material Cost |
| $\gamma$ -CD/PVA/QCS composite | PVA          | Shanghai Aladdin Biochemical Technology Co., Ltd., China | 1 Kg       | ¥203   | 0.039mg      | ¥0.0000079    |
|                                | CS           | China National Pharmaceutical Group Co., Ltd., China     | 500 g      | ¥252   | 0.007 mg     | ¥0.0000035    |
|                                | GTA          | Shanghai Macklin Biochemical Co., Ltd., China            | 250 g      | ¥116   | 0.007 mg     | ¥0.0000016    |
|                                | GA           | Shanghai Macklin Biochemical Co., Ltd., China            | 500 mL     | ¥47    | 0.052 ul     | ¥0.0000030    |
|                                | MA           | Shanghai Macklin Biochemical Co., Ltd., China            | 500 g      | ¥73    | 0.026 mg     | ¥0.0000038    |
|                                | $\gamma$ -CD | Shanghai Macklin Biochemical Co., Ltd., China            | 5g         | ¥ 184  | 0.02 mg      | ¥0.000736     |
| Chip                           | glass slide  | Yancheng Feizhou Glass Co., LTD, China                   | 50 pieces  | ¥8     | 1 piece      | ¥0.16         |
|                                | Sylgard 184  | DOW SILICONES CORPORATION, USA                           | 19.9 Kg    | ¥13500 | 2 g          | ¥1.36         |
| <b>CEC</b>                     |              |  |            |        | <b>¥1.52</b> |               |

229 **Table S6.** Pharmacokinetic parameters of Rho123 in rats after intragastrical administration of  
 230 Rho123 (5 mg/kg; n= 3, mean  $\pm$  SD) with or without treatment of VER.

| Parameters   | Negative control group | Verapamil<br>5 mg/kg | P value |
|--|------------------------|----------------------|---------|
| AUC <sub>(0-t)</sub> ( $\mu\text{g/L h}$ )                   | 38.41 $\pm$ 4.16       | 104.29 $\pm$ 5.14    | 0.00002 |
| AUC <sub>(0-<math>\infty</math>)</sub> ( $\mu\text{g/L h}$ ) | 57.15 $\pm$ 9.80       | 129.45 $\pm$ 25.18   | 0.027   |
| CLz(L/h/kg)  | 87.48 $\pm$ 11.07      | 39.69 $\pm$ 6.90     | 0.012   |
| Vz (L/kg)  | 2008.32 $\pm$ 1040.21  | 583.96 $\pm$ 273.20  | 0.047   |
| C <sub>max</sub> ( $\mu\text{g/L}$ )                         | 8.46 $\pm$ 1.80        | 20.85 $\pm$ 1.62     | 0.002   |

231

232

**Table S7 List of Abbreviations**

| <b>Abbreviations</b> | <b>Definition</b>                       |
|----------------------|---|
| AEM                  | anion-exchange membranes                |
| CEC                  | cation electrokinetic concentrator      |
| AP-BL                | Apical-to-basolateral                   |
| BER                  | Berberine                               |
| BL-AP                | Basolateral-to-apical                   |
| CBR                  | Cationic Brilliant Red                  |
| CE                   | Cationic electrophoresis                |
| CEM                  | Cation exchange membranes               |
| CS                   | Chitosan                                |
| EF                   | Enrichment factor                       |
| EOF                  | Electroosmotic flow                     |
| ER                   | Efflux ratio                            |
| GA                   | Glutaraldehyde                          |
| HPLC                 | High-performance liquid chromatography  |
| HSA                  | Human serum albumin                     |
| ICP                  | Ion concentration polarization          |
| IDZ                  | Ion depletion zone                      |
| MA                   | Melamine                                |
| MDR1                 | Multidrug resistance protein 1          |
| MS                   | Mass spectrometry                       |
| PDDAC                | Poly dimethyl diallyl ammonium chloride |
| P <sub>app</sub>     | Apparent permeability coefficient       |
| P-gp                 | P-glycoprotein                          |
| PVA                  | Polyvinyl alcohol                       |
| QCS                  | Quaternized chitosan                    |
| Rho 123              | Rhodamine 123                           |
| SEM                  | Scanning electron microscopy            |
| TEM                  | Transmission electron microscopy        |
| VER                  | Verapamil                               |
| 18 $\alpha$ -GA      | 18 $\alpha$ -glycyrrhetic acid          |
| $\gamma$ -CD         | $\gamma$ -cyclodextrin                  |

## 235 **References**

- 236 [1] M. Lee, H.J. Kwon, G. Lim, A Multiscale-Porous Anion Exchange Membrane for Convenient and  
237 Scalable Electrokinetic Concentration of Cationic Species, *Adv Funct Mater* 31 (2021).
- 238 [2] S. Yamamoto, F. Okada, M. Kinoshita, et al., On-line microchip electrophoresis-mediated  
239 preconcentration of cationic compounds utilizing cationic polyacrylamide gels fabricated by in situ  
240 photopolymerization, *Analyst* 143 (2018) 4429-4435.
- 241 [3] I.H. Shin, K.J. Kim, J. Kim, et al., Cation-selective electroconcentration, *Lab Chip* 14 (2014)  
242 1811-1815.
- 243 [4] N. Hashimoto, N. Nakamichi, S. Uwafuji, et al., ATP binding cassette transporters in two distinct  
244 compartments of the skin contribute to transdermal absorption of a typical substrate, *Journal of*  
245 *Controlled Release* 165 (2013) 54-61.
- 246 [5] E. Yu, E. Ban, M.K. In, et al., Development for the analysis of reactive oxygen species using  
247 capillary electrophoresis with laser-induced fluorescence detection, *Journal of Microcolumn*  
248 *Separations* 13 (2001) 327-331.
- 249 [6] R. Li, R.a. Wu, M. Wu, et al., MEKC-LIF analysis of rhodamine123 delivered by carbon nanotubes  
250 in K562 cells, *Electrophoresis* 30 (2009) 1906-1912.
- 251 [7] L. Xiu, M. Yuan, Y. Sun, et al., *Jiangxi Journal of Chinese Traditional Medicine* 45 (2014) 11-13.  
252